Outcome measures were the percentage of patients receiving G-CSF for primary prophylaxis versus secondary prophylaxis/treatment, duration of treatment with G-CSF and incidence of CIN-related complications. The gene discussed is CSF3; the disease is cervical squamous intraepithelial neoplasia.